Celgene’s $13.4 Billion Divestment Of Otezla

Kirkland & Ellis advised Bristol-Myers Squibb Company on the agreement with Amgen for Amgen to acquire the global rights to Celgene Corporation’s OTEZLA® for $13.4 billion in cash.

Bristol-Myers Squibb previously announced the decision to divest OTEZLA in connection with the ongoing regulatory approval process for Bristol-Myers Squibb’s pending merger with Celgene. The closing of the acquisition covered by the agreement with Amgen is contingent on Bristol-Myers Squibb and Celgene entering into a consent decree with the Federal Trade Commission (FTC) in connection with their pending merger, the closing of the pending merger, and the satisfaction of other customary closing conditions.

Morgan Stanley & Co. LLC served as financial advisor to Bristol-Myers Squibb, and Kirkland & Ellis LLP served as Bristol-Myers Squibb’s legal counsel regarding the divestiture. Arnold & Porter Kaye Scholer LLP also acted as legal counsel on antitrust matters.

The Kirkland team was led by transactional partners Daniel Wolf (Picture), Jonathan Davis and Ryan Brissette along with David Fox; technology & IP transactions partner Lisa Samenfeld and associates Frank Wei and Ashley Eisenberg; tax partners Sara Zablotney and Dean Shulman and associate Vivek Ratnam; and antitrust partner Matt Reilly.

Involved fees earner: Ryan Brissette – Kirkland & Ellis; Jonathan Davis – Kirkland & Ellis; Ashley Eisenberg – Kirkland & Ellis; David Fox – Kirkland & Ellis; Vivek Ratnam – Kirkland & Ellis; Matthew Reilly – Kirkland & Ellis; Lisa Samenfeld – Kirkland & Ellis; Dean Shulman – Kirkland & Ellis; Frank Wei – Kirkland & Ellis; Daniel Wolf – Kirkland & Ellis; Sara Zablotney – Kirkland & Ellis;

Law Firms: Kirkland & Ellis;

Clients: Bristol-Myers Squibb;

Print Friendly, PDF & Email

Author: Ambrogio Visconti